HPRA Strengthens Medical Device Vigilance Through Ongoing Field Safety Monitoring

Regulatory Update | Medical Devices | October 2026

Medical-device market access doesn't end when a product reaches the market.

For manufacturers and economic operators, ongoing monitoring of device safety and performance is a core part of the regulatory lifecycle. In Ireland, the Health Products Regulatory Authority (HPRA) continues to oversee this through Field Safety Notices (FSNs), safety communications, and other post-market surveillance activities.

On 14 October 2026, the HPRA published its monthly summary of FSNs affecting the Irish market for September 2026. The summary shows the range of corrective actions that can arise post-market, from device removals and software updates to changes in instructions for use and additional advice on how devices should be used.

For manufacturers supplying devices in Ireland, it's a timely reminder: effective vigilance systems matter, and you need to be ready to respond when safety issues emerge.

What Is a Field Safety Notice?

A Field Safety Notice (FSN) is a communication issued by a manufacturer to inform device users about a safety issue and the actions needed to reduce the associated risk. According to the HPRA, FSNs help healthcare organisations and users identify affected devices and implement corrective actions promptly.

Depending on the risk, resulting actions can include:

• Removing affected devices from the market

• Updating software

• Modifying a device

• Updating instructions for use

• Providing additional safety information

• Changing how a device is used

• Conducting further follow-up or monitoring

  
  

September 2026: A Broad Range of Safety Actions

The latest HPRA summary covered notices across medical imaging systems, patient monitoring equipment, diagnostic products, surgical devices, and software. Several involved device removals; others involved software upgrades or updates to instructions for use. One example: notices concerning the Dexcom G7 iOS CGM App involved software updates.

Why the variety matters: post-market safety actions aren't limited to physical product defects. They can also involve software, labelling, instructions for use, and how a device is operated, increasingly relevant for connected and software-enabled devices, whose safety considerations can continue long after initial market placement.

Why Post-Market Vigilance Matters

Medical-device regulation is built on the principle that safety and performance must be monitored after products reach the market. Real-world use can reveal information not identified during development, testing, or pre-market evaluation.

Manufacturers need systems that can identify and assess emerging safety signals and determine whether corrective action is required.

An important point from the HPRA: when a manufacturer issues an FSN and Field Safety Corrective Action (FSCA), affected organisations should act promptly, not wait for the HPRA to publish a separate safety notice. The manufacturer's FSN is itself a key regulatory communication; the HPRA may publish its own where broader awareness of an issue affecting the Irish market is needed.

What Is a Field Safety Corrective Action?

An FSCA is an action taken by a manufacturer to reduce a risk associated with a device already on the market. Typical measures include:

Measure	What It Involves
Device removal	Pulling affected products from healthcare facilities, distributors, or the supply chain
Software updates	Installing a new version on connected or software-dependent devices
Instructions for use changes	Providing updated information so devices are used safely and correctly
Device modification	Physical or technical changes where required
Additional safety information	New instructions or warnings about identified risks

The right action depends on the specific issue and the manufacturer's assessment.

What Manufacturers Should Do

1. Maintain effective post-market surveillance: Continuously monitor complaints, incidents, healthcare-professional feedback, distributor information, and other relevant post-market data.

2. Assess safety signals promptly. Not every complaint leads to an FSCA, but potential signals should be assessed quickly to determine whether they point to a broader issue.

3. Establish clear escalation procedures: Define how potential safety issues move from local teams and distributors to the right regulatory and safety functions.

4. Coordinate with Irish economic operators: Make sure local representatives, distributors, and other operators understand their responsibilities when a safety issue affects the Irish market.

5. Document corrective actions: The HPRA recommends keeping records of FSN receipt, affected devices identified, actions completed, dates, and responsible personnel, plus evidence that corrective actions were properly implemented.

6. Monitor regulatory communications: Track HPRA safety notices and its monthly FSN summaries covering the Irish market.

Why This Matters for International Manufacturers

For manufacturers based outside Ireland, post-market compliance gets more complex when responsibilities are spread across an authorised representative, importer, distributor, or other local partner. Without clearly defined roles, important safety communications may not reach the right people quickly enough.

Plan post-market vigilance before market entry, not as an afterthought to registration.

Be clear on:

• Who receives safety complaints

• Who assesses potential incidents

• Who communicates with the HPRA

• Who coordinates FSN distribution

• Who identifies affected devices

• Who manages corrective actions

• Who maintains regulatory records

• Who confirms completion of required actions

  
  

Clear allocation of responsibilities reduces delays when urgent action is needed.

Software-Enabled Devices Need Particular Attention

The September notices show why software belongs in your post-market surveillance strategy. A software-related issue may call for an update rather than a physical removal.

For connected devices and digital health technologies, vigilance needs to extend beyond the hardware. Consider how software changes, cybersecurity concerns, performance issues, and updates may affect safety and intended performance especially where clinical functionality depends heavily on software.

ARQon Insight

The latest HPRA summary is a clear reminder: medical-device compliance doesn't end at market entry.

A product may complete its pre-market pathway, but manufacturers remain responsible for monitoring safety and performance throughout its lifecycle. The range of corrective actions in September's summary shows just how varied post-market issues can be.

For international manufacturers, post-market vigilance should be a core part of market-access strategy. The regulatory lifecycle looks like this:

Market Entry → Monitoring → Signal Detection → Risk Assessment → Corrective Action → Regulatory Communication → Follow-Up

Our take: a company that plans only for registration is prepared for the start of the journey but not necessarily for everything that follows.

Building a Proactive Approach

Rather than responding only after an incident, build post-market surveillance into your wider compliance systems:

• Monitoring: continuously collect relevant safety and performance information

• Assessment: determine whether emerging information signals a regulatory or patient-safety concern

• Action: implement corrective or preventive measures when needed

• Communication: ensure authorities, economic operators, healthcare professionals, and users get appropriate information

• Documentation: keep evidence of decisions, communications, and corrective actions

  
  

Key Takeaway

The HPRA's September 2026 FSN summary, published 14 October 2026, highlights the continuing importance of medical-device vigilance in Ireland. Corrective actions can take many forms: device removal, software updates, changes to instructions for use, and additional advice on device use.

For manufacturers supplying devices in Ireland, the message is clear:

Market access isn't the finish line. It's the beginning of the post-market regulatory journey.

Effective vigilance, clear responsibilities, and timely corrective action are essential to maintaining compliance and protecting patients throughout the device lifecycle.

How ARQon Can Support You

ARQon supports healthcare and life-science companies with regulatory intelligence and market-access activities across international markets, including:

• Regulatory intelligence and monitoring

• Medical-device market-entry strategy

• Regulatory pathway assessment

• Post-market compliance planning

• Vigilance and regulatory monitoring

• Regulatory gap analysis

• Documentation planning

• Local market-access coordination

• Cross-border regulatory strategy

  
  

Stay Ahead. Stay Compliant. Stay Informed. With ARQon Regulatory Intelligence.

Sources

Health Products Regulatory Authority (HPRA), Ireland:

• Summary of Field Safety Notices – September 2026, published 14 October 2026

• Managing Field Safety Corrective Actions